Updates on the Evolving Role of Multidisciplinary Care Teams for the Management of Patients with Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy: The Nurse’s Role in Multidisciplinary Care
Post-Test/Evaluation

Exit Survey

Questions marked with a * are required

19%

Contact Information

First Name

Last Name

Email Address

Credentials/Degree (MD, DO, RN, etc.)

Date of Participation

At a well-child visit to their pediatrician, the parents of a 2 1/2-year-old child report that he is demonstrating a lack of coordination, particularly with walking, running, and climbing stairs. After evaluation, he is diagnosed with Duchenne muscular dystrophy, and the parents ask about gene therapy. Is this child a candidate for gene therapy at this time?

No, the patient is too young at this time (current indication for FDA-approved gene therapy is 4-5 years old)

No, the patient is too old (current indication is between 12 and 24 months)

Yes, the current indication for gene therapy is 2-3 years of age

Yes, any child of any age can receive gene therapy for DMD

Which of the following best describes the nurse’s role in managing Duchenne muscular dystrophy?

Identifying and diagnosing the disease

Selecting appropriate treatments for the patient

Performing genetic testing to determine phenotype

Coordinating patient care (eg, home equipment, physical/occupational therapy, notes to school/daycare, etc)